T cells recognizing self antigens expressed by cancer cells are prevalent in the immune repertoire. However, activation of these autoreactive T cells is limited by weak signals that are incapable of fully priming naive T cells, creating a state of tolerance or ignorance. Even if T cell activation occurs, immunity can be further restricted by a dominant response directed at only a single epitope. Enhanced antigen presentation of multiple epitopes was investigated as a strategy to overcome these barriers. Specific point mutations that create altered peptide ligands were introduced into the gene encoding a nonimmunogenic tissue self antigen expressed by melanoma, tyrosinase-related protein-1 (Tyrp1). Deficient asparagine-linked glycosylation, which was caused by additional mutations, produced altered protein trafficking and fate that increased antigen processing. Immunization of mice with mutated Tyrp1 DNA elicited cross-reactive CD8+ T cell responses against multiple nonmutated epitopes of syngeneic Tyrp1 and against melanoma cells. These multispecific anti-Tyrp1 CD8+ T cell responses led to rejection of poorly immunogenic melanoma and prolonged survival when immunization was started after tumor challenge. These studies demonstrate how rationally designed DNA vaccines directed against self antigens for enhanced antigen processing and presentation reveal novel self epitopes and elicit multispecific T cell responses to nonimmunogenic, nonmutated self antigens, enhancing immunity against cancer self antigens.
José A. Guevara-Patiño, Manuel E. Engelhorn, Mary Jo Turk, Cailian Liu, Fei Duan, Gabrielle Rizzuto, Adam D. Cohen, Taha Merghoub, Jedd D. Wolchok, Alan N. Houghton
Title and authors | Publication | Year |
---|---|---|
Exploring the Impact of mRNA Modifications on Translation Efficiency and Immune Tolerance to Self-Antigens
Sioud M, Juzeniene A, Sæbøe-Larssen S |
Human vaccines | 2024 |
Therapeutic Anti-Tumor Efficacy of DC-Based Vaccines Targeting TME-Associated Antigens Is Improved When Combined with a Chemokine-Modulating Regimen and/or Anti-PD-L1
Taylor JL, Kokolus KM, Basse PH, Filderman JN, Cosgrove CE, Watkins SC, Gambotto A, Lowe DB, Edwards RP, Kalinski P, Storkus WJ |
Human vaccines | 2024 |
Insights in AAV-mediated antigen-specific immunity and a strategy for AAV vaccine dose reduction through AAV-extracellular vesicle association
Molina E, Tejero M, Duzenli OF, Kuoch H, Caine C, Krotova K, Paulaitis M, Aslanidi G |
Molecular Therapy. Methods & Clinical Development | 2024 |
Proteolysis-targeting vaccines (PROTAVs) for robust combination immunotherapy of melanoma
Wang Q, Su T, Cheng F, Zhou S, Liu X, Wang M, Xu Y, Tang R, Liao S, Dailey J, Xiao G, Yang C, Wen H, Zheng W, Wen B, Tyc KM, Liu J, Sun D, Wang S, Zhu G |
bioRxiv | 2024 |
Tumor antigen-loaded AAV vaccine drives protective immunity in a melanoma animal model
Krotova K, Kuoch (Yoshitomi) H, Caine C, Aslanidi G |
2023 | |
Metabolic heterogeneity in early-stage lung adenocarcinoma revealed by RNA-seq and scRNA-seq.
Zhang Y, Shi J, Luo J, Liu C, Zhu L |
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2023 |
Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine
Gigoux M, Holmström MO, Zappasodi R, Park JJ, Pourpe S, Bozkus CC, Mangarin LM, Redmond D, Verma S, Schad S, George MM, Venkatesh D, Ghosh A, Hoyos D, Molvi Z, Kamaz B, Marneth AE, Duke W, Leventhal MJ, Jan M, Ho VT, Hobbs GS, Knudsen TA, Skov V, Kjær L, Larsen TS, Hansen DL, Lindsley RC, Hasselbalch H, Grauslund JH, Lisle TL, Met Ö, Wilkinson P, Greenbaum B, Sepulveda MA, Chan T, Rampal R, Andersen MH, Abdel-Wahab O, Bhardwaj N, Wolchok JD, Mullally A, Merghoub T |
Science Translational Medicine | 2022 |
HSP70iQ435A to subdue autoimmunity and support anti-tumor responses
D Jaishankar, C Cosgrove, P Ramesh, J Mahon, R Shivde, ER Dellacecca, SF Yang, J Mosenson, JA Guevara-Patiño, IC Poole |
Cell Stress and Chaperones | 2021 |
Pharmacokinetic tuning of protein–antigen fusions enhances the immunogenicity of T-cell vaccines
NK Mehta, RV Pradhan, AP Soleimany, KD Moynihan, AM Rothschilds, N Momin, K Rakhra, J Mata-Fink, SN Bhatia, KD Wittrup, DJ Irvine |
Nature Biomedical Engineering | 2020 |
Activation of CD8+ T Cell Responses after Melanoma Antigen Targeting to CD169+ Antigen Presenting Cells in Mice and Humans
D van Dinther, ML Venegas, H Veninga, K Olesek, L Hoogterp, M Revet, M Ambrosini, H Kalay, J Stöckl, Y van Kooyk, J den Haan |
Cancers | 2019 |
Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT
EK Duperret, MC Wise, A Trautz, DO Villarreal, B Ferraro, J Walters, J Yan, A Khan, E Masteller, L Humeau, DB Weiner |
Molecular Therapy | 2018 |
Designing consensus immunogens to break tolerance to self-antigens for cancer therapy
EK Duperret, J Yan, DB Weiner |
Oncotarget | 2018 |
A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity
JN Walters, B Ferraro, EK Duperret, KA Kraynyak, J Chu, A Saint-Fleur, J Yan, H Levitsky, AS Khan, NY Sardesai, DB Weiner |
Molecular Therapy | 2017 |
Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses
KD Moynihan, CF Opel, GL Szeto, A Tzeng, EF Zhu, JM Engreitz, RT Williams, K Rakhra, MH Zhang, AM Rothschilds, S Kumari, RL Kelly, BH Kwan, W Abraham, K Hu, NK Mehta, MJ Kauke, H Suh, JR Cochran, DA Lauffenburger, KD Wittrup, DJ Irvine |
Nature Medicine | 2016 |
Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines
L Vandenberk, J Belmans, MV Woensel, M Riva, SW van Gool |
Frontiers in immunology | 2016 |
Alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 can support immune responses toward tumors overexpressing ganglioside D3 in mice
Eby JM, Barse L, Henning SW, Rabelink MJ, Klarquist J, Gilbert ER, Hammer AM, Fernandez MF, Yung N, Khan S, Miller HG, Kessler ER, Garrett-Mayer E, Dilling DF, Hoeben RC, Le Poole IC |
Cancer Immunology, Immunotherapy | 2016 |
CCL22 to Activate Treg Migration and Suppress Depigmentation in Vitiligo
JM Eby, HK Kang, ST Tully, WE Bindeman, DS Peiffer, S Chatterjee, S Mehrotra, IC le Poole |
Journal of Investigative Dermatology | 2015 |
An optimized peptide vaccine strategy capable of inducing multivalent CD8 T cell responses with potent antitumor effects
HI Cho, SH Jung, HJ Sohn, E Celis, TG Kim |
OncoImmunology | 2015 |
Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma
Y Hong, Y Peng, ZS Guo, J Guevara-Patino, J Pang, LH Butterfield, NF Mivechi, DH Munn, DL Bartlett, Y He |
Hepatology | 2014 |
Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects
Y He, Y Hong, GJ Mizejewski |
Immunotherapy | 2014 |
Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy
T Liechtenstein, N Perez-Janices, I Blanco-Luquin, C Goyvaerts, J Schwarze, I Dufait, A Lanna, MD Ridder, D Guerrero-Setas, K Breckpot, D Escors |
OncoImmunology | 2014 |
Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer
A NoeDominguez-Romero, R Zamora-Alvarado, R Servín-Blanco, EG Pérez-Hernández, LE Castrillon-Rivera, ME Munguia, G Acero, T Govezensky, G Gevorkian, K Manoutcharian |
Human Vaccines & Immunotherapeutics | 2014 |
The Effect of Adjuvanting Cancer Vaccines with Herpes Simplex Virus Glycoprotein D on Melanoma-Driven CD8+ T Cell Exhaustion
Y Zhang, HC Ertl |
Journal of immunology (Baltimore, Md. : 1950) | 2014 |
Impact of Sequence Variation in a Dominant HLA-A*02-Restricted Epitope in Hepatitis C Virus on Priming and Cross-Reactivity of CD8+ T Cells
S Ziegler, K Skibbe, A Walker, X Ke, FM Heinemann, A Heinold, JY Mok, WJ van Esch, D Yang, M Wolfl, J Timm |
Journal of virology | 2014 |
Enhanced Responses to Tumor Immunization Following Total Body Irradiation Are Time-Dependent
A Diab, RR Jenq, GA Rizzuto, AD Cohen, DW Huggins, T Merghoub, ME Engelhorn, JA Guevara-Patiño, D Suh, VM Hubbard-Lucey, AA Kochman, S Chen, H Zhong, JD Wolchok, MR van Brink, AN Houghton, MA Perales, H Shiku |
PloS one | 2013 |
Mutant HSP70 Reverses Autoimmune Depigmentation in Vitiligo
JA Mosenson, A Zloza, JD Nieland, E Garrett-Mayer, JM Eby, EJ Huelsmann, P Kumar, CJ Denman, AT Lacek, FJ Kohlhapp, A Alamiri, T Hughes, SD Bines, HL Kaufman, A Overbeck, S Mehrotra, C Hernandez, MI Nishimura, JA Guevara-Patino, IC le Poole |
Science Translational Medicine | 2013 |
Cytomegalovirus-based cancer vaccines expressing TRP2 induce rejection of melanoma in mice
G Xu, T Smith, F Grey, AB Hill |
Biochemical and Biophysical Research Communications | 2013 |
Dendritic cells enhance the activity of human MUC1-stimulated mononuclear cells against breast cancer
Z Wang, MD Hall, KA Rewers-Felkins, IS Quinlin, SE Wright |
OncoImmunology | 2013 |
NKG2D signaling on CD8+ T cells represses T-bet and rescues CD4-unhelped CD8+ T cell memory recall but not effector responses
A Zloza, FJ Kohlhapp, GE Lyons, JM Schenkel, TV Moore, AT Lacek, JA O'Sullivan, V Varanasi, JW Williams, MC Jagoda, EC Bellavance, AL Marzo, PG Thomas, B Zafirova, B Polić, L Al-Harthi, AI Sperling, JA Guevara-Patiño |
Nature Medicine | 2012 |
Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma
J Pulido, T Kottke, J Thompson, F Galivo, P Wongthida, RM Diaz, D Rommelfanger, E Ilett, L Pease, H Pandha, K Harrington, P Selby, A Melcher, R Vile |
Nature Biotechnology | 2012 |
Active Immunotherapy: Current State of the Art in Vaccine Approaches for NHL
ML Palomba |
Current Oncology Reports | 2012 |
Novel Toll-like Receptor 2 Ligands for Targeted Pancreatic Cancer Imaging and Immunotherapy
AS Huynh, WJ Chung, HI Cho, VE Moberg, E Celis, DL Morse, J Vagner |
Journal of Medicinal Chemistry | 2012 |
CD8(+) T cells sabotage their own memory potential through IFN-γ-dependent modification of the IL-12/IL-15 receptor α axis on dendritic cells
FJ Kohlhapp, A Zloza, JA O'Sullivan, TV Moore, AT Lacek, MC Jagoda, J McCracken, DJ Cole, JA Guevara-Patiño |
Journal of immunology (Baltimore, Md. : 1950) | 2012 |
BiVax: A peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T cell responses
HI Cho, K Barrios, YR Lee, AK Linowski, E Celis |
Cancer Immunology, Immunotherapy | 2012 |
Intratumoral electroporation of IL-12 cDNA eradicates established melanomas by Trp2180–188-specific CD8+ CTLs in a perforin/granzyme-mediated and IFN-γ-dependent manner: application of Trp2180–188 peptides
Sin JI, Park JB, Lee IH, Park D, Choi YS, Choe J, Celis E |
Cancer Immunology, Immunotherapy | 2012 |
Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors
T Kottke, F Errington, J Pulido, F Galivo, J Thompson, P Wongthida, RM Diaz, H Chong, E Ilett, J Chester, H Pandha, K Harrington, P Selby, A Melcher, R Vile |
Nature Medicine | 2011 |
HSP70i is a critical component of the immune response leading to vitiligo
JA Mosenson, A Zloza, J Klarquist, AJ Barfuss, JA Guevara-Patino, IC le Poole |
Pigment Cell & Melanoma Research | 2011 |
Tyrosinase related protein 1 (TYRP1/gp75) in human cutaneous melanoma
G Ghanem, J Fabrice |
Molecular Oncology | 2011 |
Development of Tumor-Infiltrating CD8 + T Cell Memory Precursor Effector Cells and Antimelanoma Memory Responses Are the Result of Vaccination and TGF-β Blockade during the Perioperative Period of Tumor Resection
EC Bellavance, FJ Kohlhapp, A Zloza, JA OSullivan, J McCracken, MC Jagoda, AT Lacek, MC Posner, JA Guevara-Patino |
Journal of immunology (Baltimore, Md. : 1950) | 2011 |
New perspectives on the role of vitiligo in immune responses to melanoma.
Byrne KT, Turk MJ |
Oncotarget | 2011 |
Interferon γ limits the effectiveness of melanoma peptide vaccines
HI Cho, YR Lee, E Celis |
Blood | 2010 |
Immunization delivered by lentiviral vectors for cancer and infectious diseases
B Hu, A Tai, P Wang |
Immunological Reviews | 2010 |
Processing of tumor antigen differentially impacts the development of helper and effector CD4+ T-cell responses
D Bernard, MS Ventresca, LA Marshall, C Evelegh, Y Wan, JL Bramson |
Molecular Therapy | 2010 |
Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response
GA Rizzuto, T Merghoub, D Hirschhorn-Cymerman, C Liu, AM Lesokhin, D Sahawneh, H Zhong, KS Panageas, MA Perales, G Altan-Bonnet, JD Wolchok, AN Houghton |
Journal of Experimental Medicine | 2009 |
Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes
MD Sharma, DY Hou, Y Liu, PA Koni, R Metz, P Chandler, AL Mellor, Y He, DH Munn |
Blood | 2009 |
Lentivector Immunization Stimulates Potent CD8 T Cell Responses against Melanoma Self-Antigen Tyrosinase-Related Protein 1 and Generates Antitumor Immunity in Mice
Y Liu, Y Peng, M Mi, J Guevara-Patino, DH Munn, N Fu, Y He |
Journal of immunology (Baltimore, Md. : 1950) | 2009 |
Immune rejection of mouse tumors expressing mutated self
F Duan, Y Lin, C Liu, ME Engelhorn, AD Cohen, M Curran, S Sakaguchi, T Merghoub, S Terzulli, JD Wolchok, AN Houghton |
Cancer research | 2009 |
Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cells
J Klarquist, A Barfuss, S Kandala, MJ Reust, RK Braun, J Hu, DF Dilling, MD McKee, RE Boissy, RB Love, MI Nishimura, IC le Poole |
The American Journal of Pathology | 2009 |
Development of effective vaccines for old mice in a tumor model
DN Posnett, ME Engelhorn, Y Lin, T Merghoub, F Duan, JD Wolchok, AN Houghton |
Vaccine | 2009 |
CTL activation using the natural low-affinity epitope 222-229 from tyrosinase-related protein 1 leads to tumor rejection
KD Pavelko, MJ Hansen, LR Pease |
Cancer research | 2009 |
Mechanisms of Immunization Against Cancer Using Chimeric Antigens
ME Engelhorn, JA Guevara-Patiño, T Merghoub, C Liu, CR Ferrone, GA Rizzuto, DH Cymerman, DN Posnett, AN Houghton, JD Wolchok |
Molecular Therapy | 2008 |
Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma
YM Saenger, Y Li, KC Chiou, B Chan, G Rizzuto, SL Terzulli, T Merghoub, AN Houghton, JD Wolchok |
Cancer research | 2008 |
Dendritic cell based genetic immunization stimulates potent tumor protection dependent on CD8 CTL cells in the absence of autoimmunity
S Zhang, W Huang |
Journal of Cancer Research and Clinical Oncology | 2008 |
Recombinant lentivector as a genetic immunization vehicle for antitumor immunity
Y He, D Munn, LD Falo |
Expert Review of Vaccines | 2007 |
Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell–mediated immunity via dendritic cells
K Shimizu, Y Kurosawa, M Taniguchi, RM Steinman, S Fujii |
Journal of Experimental Medicine | 2007 |
A pilot study with a therapeutic vaccine based on hydroxyapatite ceramic particles and self-antigens in cancer patients
DR Ciocca, P Frayssinet, FD Cuello-Carrión |
Cell Stress and Chaperones | 2007 |